Volume | 0.00 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Organicell Regenerative Medicine Inc (QB) | OCEL | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.75 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0.00 | - | 1.00 - 4.80 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 2.75 | USD |
Organicell Regenerative Medicine Inc (QB) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
4.01B | 1.49B | 542.55M | 4.56M | -6.99M | -0.00 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Organicell Regenerative ... (QB) News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OCEL Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Months | 1.26 | 3.54 | 1.12 | 2.31 | 7,910 | 1.49 | 118.25% |
6 Months | 1.93 | 3.54 | 1.00 | 1.66 | 126,525 | 0.82 | 42.49% |
1 Year | 2.00 | 4.80 | 1.00 | 2.51 | 450,839 | 0.75 | 37.50% |
3 Years | 12.00 | 22.00 | 1.00 | 5.38 | 684,102 | -9.25 | -77.08% |
5 Years | 28.00 | 96.00 | 1.00 | 5.38 | 673,340 | -25.25 | -90.18% |
Organicell Regenerative ... (QB) Description
We are a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and to provide other related services. Our proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Our products and related services are principally used in the health care industry administered through doctors and clinics. The Company's leading product, ZofinTM (also known as OrganicellTM Flow). To date, the Company has obtained certain Investigation New Drug, and emergency IND approvals from the FDA, which authorized the Company to commence clinical trials or treatments in connection with the use of ZofinTM and related treatment protocols. The Company is pursuing efforts to complete ongoing clinical studies as well as obtaining approval to commence additional studies for other specific indications it has identified that the use of its products will provide more favorable and desired health related benefits for patients seeking alternative treatment options than are currently available. |